173 related articles for article (PubMed ID: 37781033)
1. Integrative analysis of multi-omics data reveals inhibition of RB1 signaling promotes apatinib resistance of hepatocellular carcinoma.
He K; An S; Liu F; Chen Y; Xiang G; Wang H
Int J Biol Sci; 2023; 19(14):4511-4524. PubMed ID: 37781033
[TBL] [Abstract][Full Text] [Related]
2. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.
Bollard J; Miguela V; Ruiz de Galarreta M; Venkatesh A; Bian CB; Roberto MP; Tovar V; Sia D; Molina-Sánchez P; Nguyen CB; Nakagawa S; Llovet JM; Hoshida Y; Lujambio A
Gut; 2017 Jul; 66(7):1286-1296. PubMed ID: 27849562
[TBL] [Abstract][Full Text] [Related]
3. Apatinib and Ginsenoside-Rb1 Synergetically Control the Growth of Hypopharyngeal Carcinoma Cells.
Li Y; He F; Zhang Y; Pan Z
Dis Markers; 2022; 2022():3833489. PubMed ID: 35069931
[TBL] [Abstract][Full Text] [Related]
4. Protein Profiling of WERI-RB1 and Etoposide-Resistant WERI-ETOR Reveals New Insights into Topoisomerase Inhibitor Resistance in Retinoblastoma.
Kakkassery V; Gemoll T; Kraemer MM; Sauer T; Tura A; Ranjbar M; Grisanti S; Joachim SC; Mergler S; Reinhard J
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409416
[TBL] [Abstract][Full Text] [Related]
5. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma.
Yang C; Qin S
Cancer Med; 2018 Sep; 7(9):4570-4583. PubMed ID: 30109780
[TBL] [Abstract][Full Text] [Related]
6. Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells.
Li X; Xu A; Li H; Zhang B; Cao B; Huang J
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1693-1701. PubMed ID: 29486282
[TBL] [Abstract][Full Text] [Related]
7. Quantitative proteomic and phosphoproteomic studies reveal novel 5-fluorouracil resistant targets in hepatocellular carcinoma.
Liu Z; Wang Y; Yao Y; Fang Z; Miao QR; Ye M
J Proteomics; 2019 Sep; 208():103501. PubMed ID: 31454556
[TBL] [Abstract][Full Text] [Related]
8. Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway.
Song YA; Ma T; Zhang XY; Cheng XS; Olajuyin AM; Sun ZF; Zhang XJ
Cancer Cell Int; 2019; 19():117. PubMed ID: 31073278
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.
Xia Y; Tang W; Qian X; Li X; Cheng F; Wang K; Zhang F; Zhang C; Li D; Song J; Zhang H; Zhao J; Yao A; Wu X; Wu C; Ji G; Liu X; Zhu F; Qin L; Xiao X; Deng Z; Kong X; Li S; Yu Y; Xi W; Deng W; Qi C; Liu H; Pu L; Wang P; Wang X
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35379737
[TBL] [Abstract][Full Text] [Related]
10. Comparative proteomic analysis of protein methylation provides insight into the resistance of hepatocellular carcinoma to 5-fluorouracil.
Liu Z; Wang Q; Mao J; Wang K; Fang Z; Miao QR; Ye M
J Proteomics; 2020 May; 219():103738. PubMed ID: 32198070
[TBL] [Abstract][Full Text] [Related]
11. Bidirectional transcription of Linc00441 and RB1 via H3K27 modification-dependent way promotes hepatocellular carcinoma.
Tang J; Xie Y; Xu X; Yin Y; Jiang R; Deng L; Tan Z; Gangarapu V; Tang J; Sun B
Cell Death Dis; 2017 Mar; 8(3):e2675. PubMed ID: 28300839
[TBL] [Abstract][Full Text] [Related]
12. Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies.
Sun Z; Zhao Z; Li G; Dong S; Huang Z; Ye L; Liang H; Qu J; Ai X; Zhang W; Chen X
Tumori; 2010; 96(1):90-6. PubMed ID: 20437864
[TBL] [Abstract][Full Text] [Related]
13. Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging.
Liang Q; Kong L; Du Y; Zhu X; Tian J
Exp Mol Med; 2019 Jul; 51(7):1-11. PubMed ID: 31285418
[TBL] [Abstract][Full Text] [Related]
14. The effect of apatinib in the treatment of sorafenib resistant metastatic hepatocellular carcinoma: A case report.
Han Z; He Z; Wang C; Wang Q
Medicine (Baltimore); 2018 Dec; 97(49):e13388. PubMed ID: 30544412
[TBL] [Abstract][Full Text] [Related]
15. KIAA1429 mediates epithelial mesenchymal transition in sorafenib-resistant hepatocellular carcinoma through m6A methylation modification.
Kuang Y; Cheng Y; Wang J; Li H; Cao X; Wang Y
Cancer Med; 2023 Mar; 12(6):7222-7233. PubMed ID: 36420693
[TBL] [Abstract][Full Text] [Related]
16. Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma.
Yang Y; Wang C; Sun H; Jiang Z; Zhang Y; Pan Z
Cancer Gene Ther; 2021 Feb; 28(1-2):89-97. PubMed ID: 32533100
[TBL] [Abstract][Full Text] [Related]
17. Proteomic Analysis Reveals that EPHX1 Contributes to 5-Fluorouracil Resistance in a Human Hepatocellular Carcinoma Cell Line.
Sun R; Dong C; Li R; Chu H; Liu J; Hao D; Zhang L; Zhao B; Wang L; Zhang Y
Proteomics Clin Appl; 2020 Jul; 14(4):e1900080. PubMed ID: 32067389
[TBL] [Abstract][Full Text] [Related]
18. Y-box binding protein 1 augments sorafenib resistance
Liu T; Xie XL; Zhou X; Chen SX; Wang YJ; Shi LP; Chen SJ; Wang YJ; Wang SL; Zhang JN; Dou SY; Jiang XY; Cui RL; Jiang HQ
World J Gastroenterol; 2021 Jul; 27(28):4667-4686. PubMed ID: 34366628
[TBL] [Abstract][Full Text] [Related]
19. Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma.
Kumar M; Kaur R; Kanthaje S; Dhiman RK; Chakraborti A
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5823-5839. PubMed ID: 36583742
[TBL] [Abstract][Full Text] [Related]
20. Quantitative proteomics identifies FOLR1 to drive sorafenib resistance via activating autophagy in hepatocellular carcinoma cells.
Chu H; Wu C; Zhao Q; Sun R; Yang K; Zhao B; Liu Y; Liang Z; Zhong S; Zhang L; Zhang Y
Carcinogenesis; 2021 May; 42(5):753-761. PubMed ID: 33677528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
